NO20023780L - Dipeptid nitril katepsin K inhibitorer - Google Patents

Dipeptid nitril katepsin K inhibitorer

Info

Publication number: NO20023780L
Authority: NO; Norway
Prior art keywords: inhibitors; dipeptide nitrile; nitrile cathepsin; cathepsin; dipeptide
Prior art date: 2000-02-10

Application number

NO20023780A

Other languages

English (en)

Norwegian (no)

Other versions

NO20023780D0 (no

Inventor

Martin Missbach

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-10

Filing date

2002-08-09

Publication date

2002-08-09

2002-08-09 Application filed by Novartis Ag filed Critical Novartis Ag

2002-08-09 Publication of NO20023780L publication Critical patent/NO20023780L/no

2002-08-09 Publication of NO20023780D0 publication Critical patent/NO20023780D0/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Tropical Medicine & Parasitology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Hematology (AREA)
Obesity (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Neurology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Hydrogenated Pyridines (AREA)
Peptides Or Proteins (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)

NO20023780A 2000-02-10 2002-08-09 Dipeptid nitril katepsin K inhibitorer NO20023780D0 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0003111.2A GB0003111D0 (en)	2000-02-10	2000-02-10	Organic compounds
PCT/EP2001/001359 WO2001058886A1 (en)	2000-02-10	2001-02-08	Dipeptide nitrile cathepsin k inhibitors

Publications (2)

Publication Number	Publication Date
NO20023780L true NO20023780L (no)	2002-08-09
NO20023780D0 NO20023780D0 (no)	2002-08-09

Family

ID=9885359

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20023780A NO20023780D0 (no)	2000-02-10	2002-08-09	Dipeptid nitril katepsin K inhibitorer

Country Status (30)

Country	Link
US (4)	US6642239B2 (zh)
EP (1)	EP1254124B1 (zh)
JP (1)	JP3942895B2 (zh)
KR (1)	KR100544553B1 (zh)
CN (2)	CN1183122C (zh)
AR (1)	AR029466A1 (zh)
AT (1)	ATE402930T1 (zh)
AU (1)	AU764334B2 (zh)
BR (1)	BR0108118A (zh)
CA (1)	CA2396158C (zh)
CO (1)	CO5261578A1 (zh)
CZ (1)	CZ20022721A3 (zh)
DE (1)	DE60135087D1 (zh)
ES (1)	ES2310177T3 (zh)
GB (1)	GB0003111D0 (zh)
HU (1)	HUP0300148A3 (zh)
IL (1)	IL150406A0 (zh)
MX (1)	MXPA02007768A (zh)
MY (1)	MY122826A (zh)
NO (1)	NO20023780D0 (zh)
NZ (1)	NZ519940A (zh)
PE (1)	PE20020220A1 (zh)
PL (1)	PL200119B1 (zh)
PT (1)	PT1254124E (zh)
RU (2)	RU2265601C2 (zh)
SK (1)	SK11462002A3 (zh)
TR (1)	TR200201752T2 (zh)
TW (1)	TWI258473B (zh)
WO (1)	WO2001058886A1 (zh)
ZA (1)	ZA200206218B (zh)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9723407D0 (en) *	1997-11-05	1998-01-07	Ciba Geigy Ag	Organic compounds
DK1178958T3 (da)	1999-03-15	2004-06-21	Axys Pharm Inc	N-cyanomethylamider som proteaseinhibitorer
GB0003111D0 (en) *	2000-02-10	2000-03-29	Novartis Ag	Organic compounds
US7723303B2 (en) *	2000-08-24	2010-05-25	The Regents Of The University Of California	Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7199102B2 (en) *	2000-08-24	2007-04-03	The Regents Of The University Of California	Orally administered peptides synergize statin activity
US7148197B2 (en) *	2000-08-24	2006-12-12	The Regents Of The University Of California	Orally administered small peptides synergize statin activity
CA2433520A1 (en)	2000-12-22	2002-07-04	Axys Pharmaceuticals, Inc.	Novel compounds and compositions as cathepsin inhibitors
US7030116B2 (en)	2000-12-22	2006-04-18	Aventis Pharmaceuticals Inc.	Compounds and compositions as cathepsin inhibitors
NZ531352A (en)	2001-09-14	2006-01-27	Aventis Pharma Inc	Novel compounds and compositions as cathepsin inhibitors
BR0214104A (pt)	2001-11-14	2004-09-28	Aventis Pharma Inc	Oligopeptìdeos e composições contendo os mesmos como inibidores de catepsina
KR100975784B1 (ko) *	2002-03-05	2010-08-17	머크 프로스트 캐나다 리미티드	카텝신 시스테인 프로테아제 억제제
AU2003298740A1 (en) *	2002-12-05	2004-06-30	Axys Pharmaceuticals, Inc.	Cyanomethyl derivatives as cysteine protease inhibitors
CA2530068A1 (en) *	2003-06-30	2005-01-06	Merck Frosst Canada Ltd.	Cyanoalklamino derivatives useful as cathepsin cysteine protease inhibitors
US20060281714A1 (en) *	2003-07-21	2006-12-14	Johann Zimmermann	Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss
WO2005049028A1 (en) *	2003-11-19	2005-06-02	Novartis Ag	Use of cathepsin k inhibitors in severe bone loss diseases
US7915300B2 (en)	2004-01-08	2011-03-29	Medivir Ab	Cysteine protease inhibitors
AU2005287004B2 (en) *	2004-09-16	2011-03-17	The Regents Of The University Of California	G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
US7579319B2 (en) *	2004-12-06	2009-08-25	The Regents Of The University Of California	Methods for improving the structure and function of arterioles
GB0427380D0 (en) *	2004-12-14	2005-01-19	Novartis Ag	Organic compounds
US20090005323A1 (en) *	2005-01-19	2009-01-01	Michael David Percival	Cathepsin K Inhibitors and Obesity
EP1841730A4 (en) *	2005-01-19	2010-10-27	Merck Frosst Canada Ltd	CATHEPSIN K INHIBITORS AND ATHEROSCLEROSIS
US20080293639A1 (en) *	2005-04-29	2008-11-27	The Regents Of The University Of California	Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
GB0517637D0 (en) *	2005-08-30	2005-10-05	Novartis Ag	Organic compounds
JP4047365B2 (ja)	2006-01-11	2008-02-13	生化学工業株式会社	シクロアルカンカルボキサミド誘導体及びその製造方法
JP3975226B2 (ja) *	2006-01-11	2007-09-12	生化学工業株式会社	シクロアルキルカルボニルアミノ酸誘導体及びその製造方法
ATE509941T1 (de)	2006-01-11	2011-06-15	Seikagaku Kogyo Co Ltd	Cycloalkylcarbonylaminosäureester-derivat und herstellungsverfahren dafür
EP2019688A2 (en) *	2006-05-22	2009-02-04	Velcura Therapeutics, Inc.	Use of cathepsin k antagonists in bone production
GB0614053D0 (en) *	2006-07-14	2006-08-23	Amura Therapeutics Ltd	Compounds
GB0614046D0 (en)	2006-07-14	2006-08-23	Amura Therapeutics Ltd	Compounds
GB0614044D0 (en) *	2006-07-14	2006-08-23	Amura Therapeutics Ltd	Compounds
KR20100023948A (ko)	2007-06-08	2010-03-04	닛뽕 케미파 가부시키가이샤	뇌동맥류의 치료 또는 예방약
BRPI0702541A2 (pt)	2007-06-21	2009-02-10	Petroleo Brasileiro Sa	processo de craqueamento catalÍtico para produÇço de diesel a partir de sementes de oleaginosas
US7893067B2 (en)	2007-06-27	2011-02-22	Medivir Ab	Cysteine protease inhibitors
JPWO2009054454A1 (ja) *	2007-10-24	2011-03-03	国立大学法人東京医科歯科大学	カテプシン阻害剤を有効成分として含有するＴｏｌｌ様受容体のシグナル伝達の調整剤
WO2009076490A1 (en) *	2007-12-12	2009-06-18	Velcura Therapeutics, Inc.	Use of cathepsin l antagonists in the treatment of bone disease
JP5587790B2 (ja)	2008-01-09	2014-09-10	アミュラセラピューティクスリミティド	化合物
WO2009103432A2 (en) *	2008-02-21	2009-08-27	Sanofi-Aventis	Covalently binding imaging probes
GB0817425D0 (en) *	2008-09-24	2008-10-29	Medivir Ab	Protease inhibitors
US20100298507A1 (en) *	2009-05-19	2010-11-25	Menschig Klaus R	Polyisobutylene Production Process With Improved Efficiencies And/Or For Forming Products Having Improved Characteristics And Polyisobutylene Products Produced Thereby
AU2012257779A1 (en)	2011-05-16	2013-11-28	Bayer Intellectual Property Gmbh	Use of cathepsin K inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure
EP2537532A1 (en)	2011-06-22	2012-12-26	J. Stefan Institute	Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use
US9593138B2 (en)	2012-10-05	2017-03-14	Wayne State University	Nitrile-containing enzyme inhibitors and ruthenium complexes thereof
WO2014199644A1 (ja)	2013-06-14	2014-12-18	生化学工業株式会社	α－オキソアシルアミノカプロラクタム誘導体
JP6226437B2 (ja)	2013-06-14	2017-11-08	生化学工業株式会社	α−オキソアシルアミノカプロラクタム体

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3467691A (en)	1964-04-22	1969-09-16	Tsutomu Irikura	N-(n-acylaminoacyl)-aminoacetonitriles
US5206249A (en)	1991-03-27	1993-04-27	Du Pont Merck Pharmaceutical Company	Bis-naphthalimides containing amino-acid derived linkers as anticancer agents
EP0547699A1 (en)	1991-12-19	1993-06-23	Merck & Co. Inc.	Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
JP3283114B2 (ja)	1992-09-07	2002-05-20	クミアイ化学工業株式会社	縮合ヘテロ環誘導体及び農園芸用殺菌剤
JP2848232B2 (ja)	1993-02-19	1999-01-20	武田薬品工業株式会社	アルデヒド誘導体
US5574064A (en)	1993-04-28	1996-11-12	Kumiai Chemical Industry Co., Ltd.	Amino-acid amide derivatives, agricultural or horticultural fungicides, and method for producing the same
AU7375194A (en) *	1993-07-30	1995-02-28	Smithkline Beecham Corporation	3-cyano-3-(3,4-disubstituted)phenylcyclohexyl-1-carboxylates
US5780498A (en)	1993-11-01	1998-07-14	Ciba-Geigy Japan Limited	Endothelin receptor antagonists
US5486623A (en) *	1993-12-08	1996-01-23	Prototek, Inc.	Cysteine protease inhibitors containing heterocyclic leaving groups
IL112759A0 (en) *	1994-02-25	1995-05-26	Khepri Pharmaceuticals Inc	Novel cysteine protease inhibitors
AU2115695A (en)	1994-03-10	1995-09-25	G.D. Searle & Co.	L-n6-(1-iminoethyl)lysine derivatives useful as nitric oxide synthase inhibitors
US5614649A (en) *	1994-11-14	1997-03-25	Cephalon, Inc.	Multicatalytic protease inhibitors
US5804560A (en) *	1995-01-06	1998-09-08	Sibia Neurosciences, Inc.	Peptide and peptide analog protease inhibitors
CA2218716A1 (en)	1995-04-21	1996-10-24	Novartis Ag	N-aroylamino acid amides as endothelin inhibitors
WO1997027200A1 (en)	1996-01-26	1997-07-31	Smithkline Beecham Plc	Thienoxazinone derivatives useful as antiviral agents
WO1998001133A1 (en)	1996-07-08	1998-01-15	Yamanouchi Pharmaceutical Co., Ltd.	Bone resorption inhibitors
EP0946499B1 (en)	1996-11-22	2005-06-01	Elan Pharmaceuticals, Inc.	N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
GB9723407D0 (en) *	1997-11-05	1998-01-07	Ciba Geigy Ag	Organic compounds
KR100518690B1 (ko)	1997-11-05	2005-10-05	노파르티스 아게	디펩타이드 니트릴
US6355678B1 (en) *	1998-06-29	2002-03-12	Parker Hughes Institute	Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
EP1155011A1 (en)	1999-02-20	2001-11-21	AstraZeneca AB	Di- and tripeptide nitrile derivatives as inhibitors of cathepsin l and cathepsin s
AU2560300A (en)	1999-02-20	2000-09-04	Astrazeneca Ab	Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsins
CA2360740A1 (en)	1999-03-02	2000-09-08	Boehringer Ingelheim Pharmaceuticals, Inc.	Compounds useful as reversible inhibitors of cathepsin s
DK1178958T3 (da)	1999-03-15	2004-06-21	Axys Pharm Inc	N-cyanomethylamider som proteaseinhibitorer
US6420364B1 (en) *	1999-09-13	2002-07-16	Boehringer Ingelheim Pharmaceuticals, Inc.	Compound useful as reversible inhibitors of cysteine proteases
IL148630A0 (en) *	1999-09-16	2002-09-12	Axys Pharm Inc	Compounds and pharmaceutical compositions for inhibiting cathepsin s
JP2001139320A (ja) *	1999-11-05	2001-05-22	Asahi Glass Co Ltd	球状シリカゲルの製造方法
ES2270898T3 (es) *	1999-12-24	2007-04-16	F. Hoffmann-La Roche Ag	Derivados de nitrilo como inhibidores de catepsina k.
WO2001049288A1 (en) *	2000-01-06	2001-07-12	Merck Frosst Canada & Co.	Novel compounds and compositions as protease inhibitors
GB0003111D0 (en) *	2000-02-10	2000-03-29	Novartis Ag	Organic compounds

2000
- 2000-02-10 GB GBGB0003111.2A patent/GB0003111D0/en not_active Ceased
2001
- 2001-02-02 TW TW090102220A patent/TWI258473B/zh not_active IP Right Cessation
- 2001-02-06 MY MYPI20010514A patent/MY122826A/en unknown
- 2001-02-07 US US09/778,302 patent/US6642239B2/en not_active Expired - Fee Related
- 2001-02-08 JP JP2001558437A patent/JP3942895B2/ja not_active Expired - Fee Related
- 2001-02-08 AT AT01919270T patent/ATE402930T1/de active
- 2001-02-08 PT PT01919270T patent/PT1254124E/pt unknown
- 2001-02-08 IL IL15040601A patent/IL150406A0/xx unknown
- 2001-02-08 RU RU2002123350/04A patent/RU2265601C2/ru not_active IP Right Cessation
- 2001-02-08 ES ES01919270T patent/ES2310177T3/es not_active Expired - Lifetime
- 2001-02-08 NZ NZ519940A patent/NZ519940A/en unknown
- 2001-02-08 EP EP01919270A patent/EP1254124B1/en not_active Expired - Lifetime
- 2001-02-08 DE DE60135087T patent/DE60135087D1/de not_active Expired - Lifetime
- 2001-02-08 PE PE2001000139A patent/PE20020220A1/es not_active Application Discontinuation
- 2001-02-08 CN CNB018048099A patent/CN1183122C/zh not_active Expired - Fee Related
- 2001-02-08 BR BR0108118-7A patent/BR0108118A/pt not_active Application Discontinuation
- 2001-02-08 AU AU46426/01A patent/AU764334B2/en not_active Ceased
- 2001-02-08 RU RU2005108133/04A patent/RU2293732C2/ru active
- 2001-02-08 SK SK1146-2002A patent/SK11462002A3/sk not_active Application Discontinuation
- 2001-02-08 CZ CZ20022721A patent/CZ20022721A3/cs unknown
- 2001-02-08 AR ARP010100563A patent/AR029466A1/es not_active Application Discontinuation
- 2001-02-08 KR KR1020027010280A patent/KR100544553B1/ko not_active Expired - Fee Related
- 2001-02-08 HU HU0300148A patent/HUP0300148A3/hu unknown
- 2001-02-08 TR TR2002/01752T patent/TR200201752T2/xx unknown
- 2001-02-08 MX MXPA02007768A patent/MXPA02007768A/es active IP Right Grant
- 2001-02-08 CN CNA2004100909449A patent/CN1636980A/zh active Pending
- 2001-02-08 PL PL357901A patent/PL200119B1/pl unknown
- 2001-02-08 CA CA002396158A patent/CA2396158C/en not_active Expired - Fee Related
- 2001-02-08 WO PCT/EP2001/001359 patent/WO2001058886A1/en not_active Ceased
- 2001-02-12 CO CO01010168A patent/CO5261578A1/es not_active Application Discontinuation
2002
- 2002-08-05 ZA ZA200206218A patent/ZA200206218B/en unknown
- 2002-08-09 NO NO20023780A patent/NO20023780D0/no unknown
2003
- 2003-04-09 US US10/410,377 patent/US20030203919A1/en not_active Abandoned
2005
- 2005-08-03 US US11/195,747 patent/US20050267129A1/en not_active Abandoned
2007
- 2007-04-23 US US11/738,878 patent/US20070191392A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2396158A1 (en)	2001-08-16
CA2396158C (en)	2010-02-02
AR029466A1 (es)	2003-07-02
RU2293732C2 (ru)	2007-02-20
CO5261578A1 (es)	2003-03-31
RU2005108133A (ru)	2006-09-10
BR0108118A (pt)	2003-02-25
RU2002123350A (ru)	2004-01-10
DE60135087D1 (de)	2008-09-11
JP2003522764A (ja)	2003-07-29
MXPA02007768A (es)	2002-10-11
CN1183122C (zh)	2005-01-05
US20050267129A1 (en)	2005-12-01
NO20023780D0 (no)	2002-08-09
WO2001058886A1 (en)	2001-08-16
JP3942895B2 (ja)	2007-07-11
SK11462002A3 (sk)	2003-01-09
PL200119B1 (pl)	2008-12-31
HK1050197A1 (zh)	2003-06-13
HUP0300148A2 (en)	2003-05-28
TR200201752T2 (tr)	2002-10-21
ATE402930T1 (de)	2008-08-15
ES2310177T3 (es)	2009-01-01
ZA200206218B (en)	2003-08-05
CZ20022721A3 (cs)	2002-11-13
PT1254124E (pt)	2008-11-03
AU764334B2 (en)	2003-08-14
CN1636980A (zh)	2005-07-13
MY122826A (en)	2006-05-31
NZ519940A (en)	2004-02-27
US20010016207A1 (en)	2001-08-23
KR100544553B1 (ko)	2006-01-24
US6642239B2 (en)	2003-11-04
HUP0300148A3 (en)	2005-04-28
GB0003111D0 (en)	2000-03-29
PL357901A1 (en)	2004-07-26
EP1254124A1 (en)	2002-11-06
PE20020220A1 (es)	2002-03-25
RU2265601C2 (ru)	2005-12-10
US20070191392A1 (en)	2007-08-16
KR20020072310A (ko)	2002-09-14
EP1254124B1 (en)	2008-07-30
TWI258473B (en)	2006-07-21
US20030203919A1 (en)	2003-10-30
AU4642601A (en)	2001-08-20
CN1398260A (zh)	2003-02-19
IL150406A0 (en)	2002-12-01

Publication	Publication Date	Title
NO20023780D0 (no)	2002-08-09	Dipeptid nitril katepsin K inhibitorer
EP1272467A4 (en)	2003-05-07	Cathepsin cysteine protease inhibitors
CY2012007I2 (el)	2014-07-02	Πεπτιδομιμητικοι αναστολεις πρωτεασης
NO20026283L (no)	2003-02-28	Inhibitorer av kobberholdige aminosydaser
NO20034044D0 (no)	2003-09-12	Metallproteinase-inhibitorer
ATE524441T1 (de)	2011-09-15	Vla-4-inhibitoren
PT1370553E (pt)	2006-09-29	Inibidores de rhoquinase
EP1499336A4 (en)	2005-06-01	PROTEASE INHIBITORS
NO20034032L (no)	2003-11-10	Metallproteinase-inhibitorer
EP1694647A4 (en)	2010-08-04	CATHEPSINCYSTEINPROTEASEHEMMER
DK1272488T3 (da)	2006-07-17	Tri-aryl-substitueret ethan-PDE4-inhibitorer
NO20025786L (no)	2003-02-12	Protaseinhibitorer
NO20025005D0 (no)	2002-10-17	Proteaseinhibitorer
DE60132468D1 (de)	2008-03-06	Alen-lanosterol zyklase inhibitoren
NO20032328D0 (no)	2003-05-22	Proteaseinhibitorer
AR028075A1 (es)	2003-04-23	Inhibidores de la peptido-desformilasa
DE60124397D1 (de)	2006-12-21	Inhibitoren von serinproteasen